NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
- 10% growth in Q4 net sales from the eyecare and wound care segment
- 27% decline in sales and marketing expenses for the quarter
- Divestiture of skincare segment to enhance cash position
- Co-marketing partnership in the eyecare market for strategic growth
- 64% year-over-year increase in online subscription-based unit sales
- None.
Insights
The reported 10% increase in Q4 net sales from the eyecare and wound care segment of NovaBay Pharmaceuticals indicates a solid performance in these areas, likely reflecting a successful adaptation to market demands and effective channel strategy. The growth in Avenova sales, both through physician dispensed and OTC channels, suggests an effective utilization of digital marketing, which is also supported by the reported reduction in sales and marketing expenses. This reduction, by 27% for the quarter, signifies a strategic shift towards more cost-efficient digital marketing tactics, which could be a positive signal for operating leverage improvement.
The divestiture of the skincare segment, DERMAdoctor, appears to be a strategic move to focus on core competencies and could result in a more streamlined operation with reduced complexity and cost structure. This refocus on the eyecare segment, including the co-marketing partnership with Eyenovia, may enhance NovaBay's market position in its specialty areas. However, investors should be mindful of the impairment charges related to the skincare segment, which may indicate challenges faced in this area and potential risks associated with divestitures.
Furthermore, the full-year financials show a modest 2% increase in total sales, with a stable gross margin. The reduction in G&A and R&D expenses could be indicative of disciplined cost management. However, the net loss attributable to common stockholders and the increase in other expenses, primarily due to interest and amortization of convertible notes, highlight the need to examine the company's capital structure and financing strategy. The decrease in cash and cash equivalents year-over-year should also be monitored closely as it may impact the company's ability to fund ongoing operations and growth initiatives.
The growth in NovaBay's eyecare and wound care segment sales reflects broader industry trends where companies that leverage online sales channels and subscriptions, such as through Amazon.com and Avenova.com, can outperform. The 64% year-over-year increase in online subscription-based unit sales underscores the importance of a strong e-commerce strategy in the healthcare products market. The company's ability to capitalize on digital marketing to drive sales while simultaneously reducing marketing expenses is a testament to the efficacy of digital optimization strategies in reaching and retaining customers.
From a market perspective, the partnership with Eyenovia could potentially open new distribution avenues and enhance product offerings, which may be a strategic move to capture additional market share. Investors should consider the potential for synergies from this partnership and how it might contribute to future revenue growth. It is also essential to consider the competitive landscape of the eyecare market and how NovaBay's growth strategy aligns with emerging trends in consumer preferences and technology adoption within the sector.
The eyecare and wound care markets are highly competitive with a significant focus on innovation and customer retention. NovaBay's reported increase in sales within these segments suggests that their product offerings, such as Avenova, are resonating with both physicians and consumers. The emphasis on physician-dispensed and over-the-counter sales channels indicates a strategic approach to market penetration, catering to different customer segments.
The reduction in R&D expenses might raise questions about the company's long-term innovation pipeline and commitment to product development. While cost reductions can benefit the bottom line in the short term, sustained R&D investment is critical for long-term competitiveness in the medical industry. Stakeholders should assess the balance between cost-saving measures and the potential impact on future product development and market competitiveness.
Moreover, the divestiture of the skincare segment may allow NovaBay to allocate resources more efficiently and focus on areas with higher growth potential. However, the impairment charges suggest that there were significant challenges within the skincare business and stakeholders should consider whether the issues leading to impairment were unique to the skincare segment or indicative of broader operational challenges.
-
Q4 net sales from the eyecare and wound care segment grew
10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from branded wound care products -
Sales and marketing expenses for the quarter declined
27% reflecting digital marketing optimization - Divestiture of skincare segment expected to bolster cash position and reduce operating expenses
- Continued execution on eyecare growth strategy including recent co-marketing partnership
Conference call begins at 4:30 p.m. Eastern time today
“Quarterly revenue from our eyecare and wound care segment increased
“Further, the declining sales from skincare products prompted the recent divestiture of DERMAdoctor®, which reduces our operating expenses and better positions us to pursue strategic initiatives that have a greater potential for growth,” he added.
“We recently announced a co-promotion agreement with Eyenovia that capitalizes on our established relationships with eyecare professionals and are seeking additional strategic growth opportunities in the eyecare market,” said Mr. Hall.
Fourth Quarter Financial Results
Total sales, net for the fourth quarter of 2023 were
Gross margin on net product revenue for the fourth quarter of 2023 was
Sales and marketing expenses for the fourth quarter of 2023 were
The Company recorded goodwill, intangible and other asset impairment charges for the fourth quarters of 2023 and 2022 of
Non-cash gain on changes in fair value of warrant liability for the fourth quarters of 2023 and 2022 were
Other expense, net for the fourth quarter of 2023 was
Net loss attributable to common stockholders for the fourth quarter of 2023 was
Full Year Financial Results
Total sales, net for 2023 were
Gross margin on net product revenue remained relatively unchanged for 2023 and 2022 at
For 2023, sales and marketing expenses decreased by
The Company recorded goodwill, intangible and other asset impairment charges for 2023 and 2022 of
Non-cash loss on modification of common stock warrants for 2023 and 2022 was
Other expense, net for 2023 was
Net loss attributable to common stockholders for 2023 was
NovaBay had cash and cash equivalents of
Conference Call
NovaBay management will host an investment community conference call today beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss the Company’s financial and operational results and answer questions. Participants can pre-register for the conference call here. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Stockholders and other interested parties may also participate in the conference call by dialing 833-816-1121 from within the
A live webcast of the call will be available here and will be archived for 90 days. A replay of the call will be available beginning two hours after the call ends through April 15, 2024 by dialing 877-344-7529 from within the
About NovaBay Pharmaceuticals, Inc.:
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in
Forward-Looking Statements
This release contains information about management's view of the Company's future expectations, plans and prospects that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts. Such forward-looking statements are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, commercial progress, current and potential future product offerings, expanded access to our products through new and existing sales channels, and any future revenue, and the timing of such revenue, that may result from selling these products, as well as generally the Company’s expected future financial results. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the Company’s products not being able to penetrate one or more targeted markets and the Company’s ability to continue as a going concern and revenues (or the execution on capital raise opportunities) not being sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K/Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
Financial tables follow
NOVABAY PHARMACEUTICALS, INC. |
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(in thousands, except par value amounts) |
||||||||
|
|
December 31, |
|
|
December 31, |
|
||
|
|
2023 |
|
|
2022 |
|
||
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
3,130 |
|
|
$ |
5,362 |
|
Accounts receivable, net of allowance for credit losses ( |
|
|
759 |
|
|
|
1,973 |
|
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ( |
|
|
2,877 |
|
|
|
3,437 |
|
Prepaid expenses and other current assets |
|
|
388 |
|
|
|
560 |
|
Total current assets |
|
|
7,154 |
|
|
|
11,332 |
|
Operating lease right-of-use assets |
|
|
1,296 |
|
|
|
1,831 |
|
Property and equipment, net |
|
|
87 |
|
|
|
119 |
|
Goodwill |
|
|
— |
|
|
|
348 |
|
Other intangible assets, net |
|
|
— |
|
|
|
2,280 |
|
Other assets |
|
|
497 |
|
|
|
489 |
|
TOTAL ASSETS |
|
$ |
9,034 |
|
|
$ |
16,399 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Liabilities: |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,130 |
|
|
$ |
1,080 |
|
Accrued liabilities |
|
|
1,516 |
|
|
|
2,724 |
|
Convertible Notes, net of discounts |
|
|
1,137 |
|
|
|
— |
|
Operating lease liabilities |
|
|
495 |
|
|
|
453 |
|
Total current liabilities |
|
|
4,278 |
|
|
|
4,257 |
|
Warrant liability |
|
|
334 |
|
|
|
— |
|
Operating lease liabilities-non-current |
|
|
1,108 |
|
|
|
1,588 |
|
Total liabilities |
|
|
5,720 |
|
|
|
5,845 |
|
Commitments and contingencies (Note 10) |
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
|
|
|
|
|
|
Series B Preferred Stock; 6 and 12 shares issued and outstanding at December 31, 2023 and 2022, respectively |
|
|
275 |
|
|
|
570 |
|
Series C Preferred Stock; 1 and 2 shares issued and outstanding at December 31, 2023 and 2022, respectively |
|
|
1,675 |
|
|
|
2,403 |
|
Common stock, |
|
|
112 |
|
|
|
20 |
|
Additional paid-in capital* |
|
|
176,101 |
|
|
|
165,713 |
|
Accumulated deficit |
|
|
(174,849 |
) |
|
|
(158,152 |
) |
Total stockholders’ equity |
|
|
3,314 |
|
|
|
10,554 |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
9,034 |
|
|
$ |
16,399 |
|
|
* |
After giving retroactive effect to a 1-for-35 reverse stock split that became effective November 15, 2022.
|
NOVABAY PHARMACEUTICALS, INC. |
||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(in thousands, except per share data) |
||||||||||||||||
Three Months Ended December 31, |
|
Year Ended December 31, |
||||||||||||||
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
||
Sales: | ||||||||||||||||
Product revenue, net | $ | 3,716 |
|
$ | 3,631 |
|
$ | 14,687 |
|
$ | 14,374 |
|
||||
Other revenue, net | 11 |
|
12 |
|
39 |
|
30 |
|
||||||||
Total sales, net | 3,727 |
|
3,643 |
|
14,726 |
|
14,404 |
|
||||||||
Product cost of goods sold | 1,912 |
|
1,888 |
|
6,831 |
|
6,623 |
|
||||||||
Gross profit | 1,815 |
|
1,755 |
|
7,895 |
|
7,781 |
|
||||||||
Operating expenses: | ||||||||||||||||
Research and development | 4 |
|
66 |
|
68 |
|
174 |
|
||||||||
Sales and marketing | 1,414 |
|
1,938 |
|
6,500 |
|
7,798 |
|
||||||||
General and administrative | 1,195 |
|
2,440 |
|
6,330 |
|
7,489 |
|
||||||||
Goodwill, intangible and other asset impairment | 2,593 |
|
6,737 |
|
2,593 |
|
6,737 |
|
||||||||
Total operating expenses | 5,206 |
|
11,181 |
|
15,491 |
|
22,198 |
|
||||||||
Operating loss | (3,391 |
) |
(9,426 |
) |
(7,596 |
) |
(14,417 |
) |
||||||||
Non-cash loss on modification of common stock warrants | (7 |
) |
- |
|
(292 |
) |
(1,922 |
) |
||||||||
Non-cash gain on changes in fair value of warrant liability | 56 |
|
976 |
|
272 |
|
5,446 |
|
||||||||
Non-cash gain on changes in fair value of contingent liability | - |
|
342 |
|
- |
|
561 |
|
||||||||
Non-cash gain on changes in fair value of combined derivative liability | - |
|
- |
|
40 |
|
- |
|
||||||||
Other expense, net | (766 |
) |
(98 |
) |
(2,064 |
) |
(276 |
) |
||||||||
Net loss | $ | (4,108 |
) |
$ | (8,206 |
) |
$ | (9,640 |
) |
$ | (10,608 |
) |
||||
Less: Increase to accumulated deficit due to adjustment | ||||||||||||||||
to Preferred Stock conversion prices | 5,061 |
|
- |
|
7,057 |
|
5,657 |
|
||||||||
Net loss attributable to common stockholders | $ | (9,169 |
) |
$ | (8,206 |
) |
$ | (16,697 |
) |
$ | (16,265 |
) |
||||
Net loss per share attributable to common stockholders (basic and diluted) * | (1.33 |
) |
$ | (4.33 |
) |
$ | (3.96 |
) |
$ | (10.10 |
) |
|||||
Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) * | 6,897 |
|
1,893 |
|
4,215 |
|
1,610 |
|
||||||||
* After giving retroactive effect to a 1-for-35 reverse stock split that became effective November 15, 2022. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326316206/en/
NovaBay
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com
Investor
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Source: NovaBay Pharmaceuticals, Inc.
FAQ
What was the percentage increase in Q4 net sales from the eyecare and wound care segment for NovaBay Pharmaceuticals (NBY)?
How much did sales and marketing expenses decline by in the quarter mentioned in the press release for NovaBay Pharmaceuticals (NBY)?
What strategic move did NovaBay Pharmaceuticals (NBY) make to enhance its cash position according to the press release?
What growth strategy is NovaBay Pharmaceuticals (NBY) focusing on in the eyecare market?